Targeting the TGFβ signalling pathway in disease
- PMID: 23000686
- PMCID: PMC3520610
- DOI: 10.1038/nrd3810
Targeting the TGFβ signalling pathway in disease
Abstract
Many drugs that target transforming growth factor-β (TGFβ) signalling have been developed, some of which have reached Phase III clinical trials for a number of disease applications. Preclinical and clinical studies indicate the utility of these agents in fibrosis and oncology, particularly in augmentation of existing cancer therapies, such as radiation and chemotherapy, as well as in tumour vaccines. There are also reports of specialized applications, such as the reduction of vascular symptoms of Marfan syndrome. Here, we consider why the TGFβ signalling pathway is a drug target, the potential clinical applications of TGFβ inhibition, the issues arising with anti-TGFβ therapy and how these might be tackled using personalized approaches to dosing, monitoring of biomarkers as well as brief and/or localized drug-dosing regimens.
Figures
Similar articles
-
Targeting the TGFβ pathway for cancer therapy.Pharmacol Ther. 2015 Mar;147:22-31. doi: 10.1016/j.pharmthera.2014.11.001. Epub 2014 Nov 6. Pharmacol Ther. 2015. PMID: 25444759 Review.
-
Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling.Ann Rheum Dis. 2015 Jul;74(7):1408-16. doi: 10.1136/annrheumdis-2013-204508. Epub 2014 Feb 23. Ann Rheum Dis. 2015. PMID: 24567525
-
Targeting TGFbeta-mediated processes in cancer.Curr Opin Drug Discov Devel. 2009 Mar;12(2):253-63. Curr Opin Drug Discov Devel. 2009. PMID: 19333871 Review.
-
The TGFBeta pathway as a therapeutic target in cancer.Clin Transl Oncol. 2008 Jan;10(1):14-9. doi: 10.1007/s12094-008-0148-2. Clin Transl Oncol. 2008. PMID: 18208788 Review.
-
Large- and small-molecule inhibitors of transforming growth factor-beta signaling.Curr Opin Investig Drugs. 2006 Jun;7(6):513-21. Curr Opin Investig Drugs. 2006. PMID: 16784021 Review.
Cited by
-
Integrating bulk RNA-seq and scRNA-seq analyses revealed the function and clinical value of thrombospondins in colon cancer.Comput Struct Biotechnol J. 2024 May 17;23:2251-2266. doi: 10.1016/j.csbj.2024.05.021. eCollection 2024 Dec. Comput Struct Biotechnol J. 2024. PMID: 38827236 Free PMC article.
-
DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care.Cancers (Basel). 2024 Apr 19;16(8):1573. doi: 10.3390/cancers16081573. Cancers (Basel). 2024. PMID: 38672654 Free PMC article. Review.
-
TANGO1 inhibitors reduce collagen secretion and limit tissue scarring.Nat Commun. 2024 Apr 24;15(1):3302. doi: 10.1038/s41467-024-47004-1. Nat Commun. 2024. PMID: 38658535 Free PMC article.
-
Tyrosine hydroxylase inhibits HCC progression by downregulating TGFβ/Smad signaling.Eur J Med Res. 2024 Apr 12;29(1):228. doi: 10.1186/s40001-024-01703-z. Eur J Med Res. 2024. PMID: 38610044 Free PMC article.
-
Delivery technologies for therapeutic targeting of fibronectin in autoimmunity and fibrosis applications.Adv Drug Deliv Rev. 2024 Jun;209:115303. doi: 10.1016/j.addr.2024.115303. Epub 2024 Apr 6. Adv Drug Deliv Rev. 2024. PMID: 38588958 Review.
References
-
- Schmierer B, Hill CS. TGFβ-SMAD signal transduction: molecular specificity and functional flexibility. Nature Rev. Mol. Cell Biol. 2007;8:970–982. - PubMed
-
- Derynck R, Miyazono K, editors. The TGF-β Family. Cold Spring Harbor Press; 2008. - PubMed
-
- Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-β family proteins in development and disease. Nature Cell Biol. 2007;9:1000–1004. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources